Medigen Biotechnology (TPEX:3176) - Share price, News & Analysis

3176 fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

3176 Stock Overview

Medigen Biotechnology Corp., a biopharmaceutical company, focuses on the development of therapies for liver diseases and cancers in Taiwan.

Rewards

Trading at 69.2% below our estimate of its fair value

Earnings have grown 14.9% per year over the past 5 years

Risk Analysis

No risks detected for 3176 from our risk checks.

Medigen Biotechnology Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Medigen Biotechnology
Historical stock prices
Current Share Price	NT$47.30
52 Week High	NT$90.00
52 Week Low	NT$44.40
Beta	0.69
1 Month Change	-16.73%
3 Month Change	-9.91%
1 Year Change	-30.65%
3 Year Change	-35.03%
5 Year Change	-12.25%
Change since IPO	147.64%

Shareholder Returns

	3176	TW Biotechs	TW Market
7D	-0.9%	0.5%	1.5%
1Y	-30.6%	7.3%	-0.7%

Return vs Industry: 3176 underperformed the TW Biotechs industry which returned 7.3% over the past year.

Return vs Market: 3176 underperformed the TW Market which returned -0.7% over the past year.

Price Volatility

Is 3176's price volatile compared to industry and market?
3176 volatility
3176 Average Weekly Movement	5.1%
Biotechs Industry Average Movement	5.2%
Market Average Movement	4.6%
10% most volatile stocks in TW Market	8.2%
10% least volatile stocks in TW Market	2.2%

Stable Share Price: 3176 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: 3176's weekly volatility (5%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1999	n/a	Stanley Chang	https://www.medigen.com.tw

Medigen Biotechnology Corp., a biopharmaceutical company, focuses on the development of therapies for liver diseases and cancers in Taiwan. It offers cell therapies, such as MAGICELL-NK, which are natural killer cells; and MAGICELL-GDT, which are T cells. It also develops OBP-301 that has completed Phase I clinical trials in combination with radiation for the treatment of esophageal cancer in Japan; is in Phase I clinical trials in combination with immune checkpoint inhibitors (ICI) for patients with esophageal cancer in Japan; and in phase II study in combination with ICI for esophageal cancer and gastric cancer patients in the United States.

Medigen Biotechnology Fundamentals Summary

How do Medigen Biotechnology's earnings and revenue compare to its market cap?
3176 fundamental statistics
Market Cap	NT$6.59b
Earnings (TTM)	-NT$70.22m
Revenue (TTM)	NT$4.22b

1.6x

P/S Ratio

-93.9x

P/E Ratio

Is 3176 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
3176 income statement (TTM)
Revenue	NT$4.22b
Cost of Revenue	NT$1.48b
Gross Profit	NT$2.74b
Other Expenses	NT$2.81b
Earnings	-NT$70.22m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-0.50
Gross Margin	64.83%
Net Profit Margin	-1.66%
Debt/Equity Ratio	10.6%

How did 3176 perform over the long term?

See historical performance and comparison

Valuation

Is Medigen Biotechnology undervalued compared to its fair value and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

>50%

Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: 3176 (NT$47.3) is trading below our estimate of fair value (NT$153.47)

Significantly Below Fair Value: 3176 is trading below fair value by more than 20%.

Price To Earnings Ratio

PE vs Industry: 3176 is unprofitable, so we can't compare its Price-To-Earnings Ratio to the TW Biotechs industry average.

PE vs Market: 3176 is unprofitable, so we can't compare its Price-To-Earnings Ratio to the TW market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 3176's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: 3176 is good value based on its Price-To-Book Ratio (2.7x) compared to the TW Biotechs industry average (3.8x).

Future Growth

How is Medigen Biotechnology forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

143.5%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Medigen Biotechnology has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Past Performance

How has Medigen Biotechnology performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

14.9%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 3176 is currently unprofitable.

Growing Profit Margin: 3176 is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: 3176 is unprofitable, but has reduced losses over the past 5 years at a rate of 14.9% per year.

Accelerating Growth: Unable to compare 3176's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 3176 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-29%).

Return on Equity

High ROE: 3176 has a negative Return on Equity (16.03%), as it is currently unprofitable.

Financial Health

How is Medigen Biotechnology's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: 3176's short term assets (NT$4.7B) exceed its short term liabilities (NT$902.2M).

Long Term Liabilities: 3176's short term assets (NT$4.7B) exceed its long term liabilities (NT$790.8M).

Debt to Equity History and Analysis

Debt Level: 3176 has more cash than its total debt.

Reducing Debt: 3176's debt to equity ratio has reduced from 31.7% to 10.6% over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable 3176 has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: 3176 is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 10.5% per year.

Dividend

What is Medigen Biotechnology current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate 3176's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 3176's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 3176's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 3176's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as 3176 has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

CEO

Stanley Chang (62 yo)

no data

Tenure

Dr. Shi-Chung Chang, also known as Stanley, MD, Ph D., serves as the Chairman and Chief Executive Officer of Medigen Biotechnology Corporation. Dr. Chang is a Urological surgeon by training, and was former...

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Data	Last Updated (UTC time)
Company Analysis	2022/05/24 00:00
End of Day Share Price	2022/05/23 00:00
Earnings	2022/03/31
Annual Earnings	2021/12/31